Squarepoint
CRL icon

Squarepoint’s Charles River Laboratories CRL Stock Holding History

Squarepoint’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,600
Closed -$720K – 4361
2025
Q3 		$720K Sell
4,600
-5,900
-56% -$937K ﹤0.01% 2931
2025
Q2 		$1.59M Buy
+10,500
New +$1.4M ﹤0.01% 2265
2024
Q2 		– Sell
-3,200
Closed -$867K – 4147
2024
Q1 		$867K Buy
+3,200
New +$764K ﹤0.01% 2692

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Squarepoint's CRL Position: Q2 2026 in Review

Squarepoint increased its Charles River Laboratories (CRL) stake by 960% in Q2 2026, buying an estimated $2.24M and bringing the position to 13,863 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1973.

Squarepoint first reported a position in CRL in Q2 2015 and has held it in 36 quarters since. The position peaked at $17.6M in Q1 2022. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Squarepoint held 13,863 shares of Charles River Laboratories worth $3.14M as of Q2 2026.
  • Squarepoint bought 12,555 Charles River Laboratories shares in Q2 2026, an estimated $2.24M.
  • Charles River Laboratories made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1973 holding.
  • Squarepoint first reported a position in Charles River Laboratories in Q2 2015 and has held it in 36 quarters since.
  • Squarepoint's Charles River Laboratories position peaked at $17.6M in Q1 2022.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.